Ethris GmbH is a biotechnology company specializing in RNA-based therapeutics and drug-delivery technologies. The company develops formulations and delivery systems, including lipid nanoparticle (LNP) platforms, to enable targeted delivery of nucleic acids such as mRNA and siRNA for therapeutic and vaccine applications.
Ethris focuses on diseases where localized and efficient delivery is critical, with notable work in respiratory indications and other inflammatory or genetic disorders. Its activities span discovery through early development, with an emphasis on scalable formulations and partnerships with industry to advance nucleic acid medicines. Ethris operates in Germany and contributes to the interface of chemistry, materials science, and biotechnology through its expertise in nanoparticle design and nucleic acid formulation.